Objective To compare the epidemiological and economic impact of additional cross-
protection against oncogenic human papillomavirus (HPV) types beyond 16/18 of the …

Background: The burden of anogenital warts will be a determining factor when making
decisions about the type of human papillomavirus (HPV) vaccine to be used (bivalent or …

A critical review of cost-effectiveness analyses of HPV vaccination in males was conducted
and nine studies were identified in different countries. Due to the heterogeneity among these …

The annual direct medical cost attributable to human papillomavirus (HPV) in the United
States over the period 2004–2007 was estimated at $9.36 billion in 2012 (updated to 2020 …

Objective: Two human papillomavirus (HPV) vaccines are on the market. Based on expected
differences in sustained-and cross-protection between the two vaccines, their long-term …

Introduction The objectives of this study were to estimate the economic burden of HPV in
Italy, accounting for total direct medical costs associated with nine major HPV-related …

Methods We adapted an existing mathematical model of HPV transmission and associated
diseases to estimate the lifetime number of diagnosed cases of disease (genital warts; …

Objective To describe the burden and the predictors of genital warts (GWs) in Czech men
and women. Methods A population-based cross-sectional study was conducted of 32 974 …

The recent approval of human papillomavirus (HPV) vaccine means that decision makers
need information beyond that available from randomized clinical trials to recommend …

Background Low-and middle-income countries (LMICs) face a number of challenges in
implementing cervical cancer prevention programmes that do not apply in high-income …